The mainstay of treatment for acute asthma is inhaled ß 2-agonists. Oral ß 2-agonists, such as terbutaline, are generally not indicated in the ED. The 2 agents that are available for parenteral ...

This summer’s family barbecue was supposed to be a celebration of sorts—coming together for the first time since the pandemic pulled the plug on group activities. But your joy was cut short by an ...

Scientists from the University of Sharjah think monoclonal antibodies hold the potential to be a far better treatment for asthma exacerbations than conventional therapies like steroids. They also ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in ... or a visit to an emergency room, although, depemokimab missed the mark on ...

If inhalers alone don’t control symptoms, add-on treatments such as leukotriene ... 5 to 10 per cent of patients with asthma ...